Product InformationRegistration Status: Active
DEXALTIN ORAL PASTE 1mg/G is approved to be sold in Singapore with effective from 1990-11-30. It is marketed by PHARMAFORTE SINGAPORE PTE LTD, with the registration number of SIN05232P.
This product contains Dexamethasone 1mg/g in the form of PASTE. It is approved for SUBMUCOSAL use.
This product is manufactured by NIPPON KAYAKU CO LTD in JAPAN.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]
Injection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
Mechanism of Action
Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Oral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone | 1-Dehydro-16α-methyl-9α-fluorohydrocortisone | 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol | 16α-Methyl-9α-fluoro-1-dehydrocortisol | 9alpha-Fluoro-16alpha-methylprednisolone | 9α-Fluoro-16α-methylprednisolone | Dexametasona | Dexamethasone | Dexamethasonum | Dexamethasone |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.